9 results on '"Clo, M."'
Search Results
2. Aderenza alla terapia antidepressiva in Emilia-Romagna
- Author
-
POLUZZI, ELISABETTA, PICCINNI, CARLO, Sangiorgi E, Clo M., Istituto Superiore di Sanità, Poluzzi E, Sangiorgi E, Piccinni C, and Clo M
- Subjects
ADERENZA AL TRATTAMENTO ,ANTIDEPRESSIVI - Published
- 2012
3. The performance guarantee of static priority scheduling for periodic real time traffic in input queued switches
- Author
-
Bonuccelli, MAURIZIO ANGELO and Clo', M. C.
- Published
- 2001
4. EDD Algorithm Performance Guarantee for Periodic Hard-Real-Time Scheduling in Distributed Systems
- Author
-
Bonuccelli, MAURIZIO ANGELO and Clo', M. C.
- Published
- 1999
5. Cycle time distribution of cyclic networks with blocking
- Author
-
Balsamo, S., Clo, M. C., and Donatiello, L.
- Published
- 1993
- Full Text
- View/download PDF
6. Use of antihistamines and risk of ventricular tachyarrhythmia: a nested case-control study in five European countries from the ARITMO project
- Author
-
Elisabetta Poluzzi, Gianluca Trifirò, Giuseppe Boriani, M. A. J. de Ridder, Serena Pecchioli, F. De Ponti, Ariola Koci, Irene D. Bezemer, Tania Schink, Alessandro Oteri, M. Clo, S. Pilgaard Ulrichsen, M C J M Sturkenboom, Igor Diemberger, Medical Informatics, Poluzzi, Elisabetta, Diemberger, I., De Ridder, M., Koci, A., Clo, M., Oteri, A., Pecchioli, S., Bezemer, I., Schink, T., Pilgaard Ulrichsen, S., Boriani, G., Sturkenboom, M. C. J., De Ponti, F., and Trifirã², G.
- Subjects
Male ,Ebastine ,030204 cardiovascular system & hematology ,Loratadine ,Antihistamine ,Levocetirizine ,0302 clinical medicine ,Antihistamines ,Arrhythmia ,Case-control study ,Drug safety ,Healthcare databases ,Aged ,Case-Control Studies ,Europe ,Female ,Histamine Antagonists ,Humans ,Middle Aged ,Odds Ratio ,Risk ,Tachycardia, Ventricular ,Pharmacology ,Pharmacology (medical) ,Tachycardia ,Terfenadine ,DRUG ,Desloratadine ,General Medicine ,HYDROXYZINE ,SAFETY ,Anesthesia ,Cohort ,HEART ,medicine.drug ,medicine.medical_specialty ,Healthcare database ,03 medical and health sciences ,Internal medicine ,medicine ,INTERVAL ,business.industry ,Ventricular ,QT PROLONGATION ,Odds ratio ,Nested case-control study ,business ,030217 neurology & neurosurgery - Abstract
Purpose: After regulatory restrictions for terfenadine and astemizole in ‘90s, only scarce evidence on proarrhythmic potential of antihistamines has been published. We evaluate the risk of ventricular tachyarrhythmia (VA) related to the use of individual antihistamines. Methods: A matched case-control study nested in a cohort of new users of antihistamines was conducted within the EU-funded ARITMO project. Data on 1997–2010 were retrieved from seven healthcare databases: AARHUS (Denmark), GEPARD (Germany), HSD and ERD (Italy), PHARMO and IPCI (Netherlands) and THIN (UK). Cases of VA were selected and up to 100 controls were matched to each case. The odds ratio (OR) of current use for individual antihistamines (AHs) was estimated using conditional logistic regression. Results: For agents largely used to prevent allergic symptoms, such as cetirizine, levocetirizine, loratadine, desloratadine and fexofenadine, we found no VA risk. A statistically significant, increased risk of VA was found only for current use of cyclizine in the pooled analysis (ORadj, 5.3; 3.6–7.6) and in THIN (ORadj, 5.3; 95% CI, 3.7–7.6), for dimetindene in GEPARD (ORadj, 3.9; 1.1–14.7) and for ebastine in GEPARD (ORadj, 3.3; 1.1–10.8) and PHARMO (ORadj, 4.6; 1.3–16.2). Conclusions: The risk of VA associated with a few specific antihistamines could be ascribable to heterogeneity in pattern of use or in receptor binding profile.
- Published
- 2017
7. Trend in SSRI-SNRI antidepressants prescription over a 6-year period and predictors of poor adherence
- Author
-
Carlo Piccinni, E Sangiorgi, Ilaria Tarricone, Marco Menchetti, Massimo Clo, Fabrizio De Ponti, Elisabetta Poluzzi, Poluzzi E, Piccinni C, Sangiorgi E, Clo M, Tarricone I, Menchetti M, and De Ponti F
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Medication Adherence ,Young Adult ,Internal medicine ,medicine ,Escitalopram ,Humans ,Pharmacology (medical) ,Neurotransmitter Uptake Inhibitors ,Medical prescription ,Psychiatry ,Aged ,Pharmacology ,Aged, 80 and over ,Sertraline ,business.industry ,General Medicine ,Odds ratio ,Middle Aged ,medicine.disease ,ANTIDEPRESSANTS ,Comorbidity ,Antidepressive Agents ,Drug Utilization ,SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) ,Regimen ,predictors ,Defined daily dose ,Italy ,Cohort ,Female ,ADHERENCE TO TREATMENT ,business ,medicine.drug - Abstract
PURPOSE: To describe antidepressant (AD) use in the Emilia-Romagna Region (Italy) and to evaluate adherence to treatment with selective serotonin receptor inhibitors or selective noradrenaline receptor inhibitors (SSRI-SNRI). METHODS: Reimbursed prescriptions of AD were retrieved from the Emilia-Romagna Regional Health Authority Database. The overall AD consumption from the 2006-2011 period was expressed in terms of prevalence and amount of use. Adherence to treatment was assessed in a cohort of patients who received SSRI-SNRI, and was followed throughout a 6-month period from the start of each treatment episode. Adherence was considered according to three parameters: duration of treatment ≥ 120 days, prescription coverage ≥ 80 %, and gaps between prescriptions < 3 months. Determinants of non-adherent regimen, including sociodemographic and clinical variables, were identified by multivariate logistic regression by calculating adjusted Odds Ratio (adjOR) and the relevant 95 % confidence interval (95CI). RESULTS: From 2006 to 2011, the prevalence of use of AD increased by 5 % (from 86 to 90 per 1,000 inhabitants) and the amount of antidepressant consumption increased by 20 % (from 43 to 51 defined daily dose per thousand inhabitants per day [DDD/TID]), with a 14 % rise in the intensity of drug use (from 182 to 208 DDD per patient). Out of 347,615 SSRI-SNRI treatment episodes, only 23.8 % were adherent. Comorbidity (adjOR:0.69; 95CI:0.67-0.72) and recurrence of AD treatment in the previous year (0.91; 0.89-0.92) were associated with better adherence. Moreover, patients treated with duloxetine (0.58; 0.55-0.60), escitalopram (0.64; 0.62-0.66) or sertraline (0.65; 0.64-0.67) showed better adherence in comparison with paroxetine. CONCLUSIONS: Clinical variables resulting in improved adherence seem to identify patients with more severe disorders and who actually need a pharmacological approach, whereas differences in adherence among ADs could in part be caused by channeling and sponsorship bias. Initiatives addressed at improving cooperation between primary care and psychiatrists could decrease AD prescription for cases of sub-threshold or mild depression that easily drop out because of rapid symptom relief or side effects.
- Published
- 2013
8. Health services utilization in patients with eating disorders: evidence from a cohort study in Emilia-Romagna.
- Author
-
Piazza A, Rucci P, Clo M, Gibertoni D, Camellini L, Di Stani M, Fantini MP, Ferri M, and Fioritti A
- Subjects
- Adolescent, Adult, Child, Feeding and Eating Disorders epidemiology, Female, Humans, Italy, Male, Middle Aged, Prevalence, Young Adult, Feeding and Eating Disorders therapy, Health Services statistics & numerical data, Patient Acceptance of Health Care
- Abstract
Purpose: To estimate the treated prevalence of eating disorders (ED) in Emilia-Romagna, Italy, and to compare health services utilization among age groups and geographical areas., Methods: The study cohort consists of patients aged 12-64 years with a primary or secondary ED diagnosis, treated in regional healthcare facilities in 2012. Patients were followed up for 1 year from the first contact. Data were extracted from regional administrative databases., Results: The study cohort included 1550 cases, 36.8 % with anorexia nervosa, 21.9 % with bulimia nervosa and 41.3 % with ED not otherwise specified. Adolescents (12-17 years) were 18.6 %, young adults (18-30) 32.7 % and older adults (31-64) 48.7 %. The annual treated prevalence rate was 5.2/10,000 (13.3 for adolescents, 9.3 for young adults and 3.4 for older adults) and was highest among adolescent (24.6/10,000) and young adult females (17.1/10,000). Cases without a record for ED in the previous year were 46.8 %. Older adults displayed higher comorbidity and used more services including hospital-based care. Outpatient care greatly exceeded inpatient care across age groups. Variations in care patterns across regional areas were found., Conclusions: Our results indicate that the care pathway for ED varies among age groups and geographical areas, but is consistent with the regional care model that favors the use of outpatient services. Future perspectives include evaluating the integration among mental health services, specialty outpatient units and primary care.
- Published
- 2016
- Full Text
- View/download PDF
9. Trend in SSRI-SNRI antidepressants prescription over a 6-year period and predictors of poor adherence.
- Author
-
Poluzzi E, Piccinni C, Sangiorgi E, Clo M, Tarricone I, Menchetti M, and De Ponti F
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Italy, Male, Middle Aged, Young Adult, Antidepressive Agents therapeutic use, Drug Utilization statistics & numerical data, Medication Adherence statistics & numerical data, Neurotransmitter Uptake Inhibitors therapeutic use
- Abstract
Purpose: To describe antidepressant (AD) use in the Emilia-Romagna Region (Italy) and to evaluate adherence to treatment with selective serotonin receptor inhibitors or selective noradrenaline receptor inhibitors (SSRI-SNRI)., Methods: Reimbursed prescriptions of AD were retrieved from the Emilia-Romagna Regional Health Authority Database. The overall AD consumption from the 2006-2011 period was expressed in terms of prevalence and amount of use. Adherence to treatment was assessed in a cohort of patients who received SSRI-SNRI, and was followed throughout a 6-month period from the start of each treatment episode. Adherence was considered according to three parameters: duration of treatment ≥ 120 days, prescription coverage ≥ 80 %, and gaps between prescriptions < 3 months. Determinants of non-adherent regimen, including sociodemographic and clinical variables, were identified by multivariate logistic regression by calculating adjusted Odds Ratio (adjOR) and the relevant 95 % confidence interval (95CI)., Results: From 2006 to 2011, the prevalence of use of AD increased by 5 % (from 86 to 90 per 1,000 inhabitants) and the amount of antidepressant consumption increased by 20 % (from 43 to 51 defined daily dose per thousand inhabitants per day [DDD/TID]), with a 14 % rise in the intensity of drug use (from 182 to 208 DDD per patient). Out of 347,615 SSRI-SNRI treatment episodes, only 23.8 % were adherent. Comorbidity (adjOR:0.69; 95CI:0.67-0.72) and recurrence of AD treatment in the previous year (0.91; 0.89-0.92) were associated with better adherence. Moreover, patients treated with duloxetine (0.58; 0.55-0.60), escitalopram (0.64; 0.62-0.66) or sertraline (0.65; 0.64-0.67) showed better adherence in comparison with paroxetine., Conclusions: Clinical variables resulting in improved adherence seem to identify patients with more severe disorders and who actually need a pharmacological approach, whereas differences in adherence among ADs could in part be caused by channeling and sponsorship bias. Initiatives addressed at improving cooperation between primary care and psychiatrists could decrease AD prescription for cases of sub-threshold or mild depression that easily drop out because of rapid symptom relief or side effects.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.